A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
Status:
Terminated
Trial end date:
2019-07-05
Target enrollment:
Participant gender:
Summary
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a difficult disease to both diagnose
and treat. It is defined as an unpleasant sensation (pain, pressure, or discomfort) perceived
to be related to the urinary bladder and associated with lower urinary tract symptoms for at
least 6 weeks duration, in the absence of infection or other identifiable causes. Pain is the
universal symptom, but many also experience symptoms of overactive bladder, possibly directly
related to the mechanism of pain. Treating pain may influence the symptom of urgency, if the
urge arises from a need to alleviate pain. In some patients whose pain improves with
treatment, troubling overactive bladder symptoms still remain. Beta-3 adrenergic agonists
have been found to decrease signaling of C-fibers in animal models. So, the investigators
hypothesize that mirabegron, which is FDA-approved for treatment of overactive bladder, would
also improve symptoms in patients with BPS/IC. As a selective beta-3 agonist, mirabegron acts
on the beta-3 receptors found in the bladder which mediate relaxation of the detrusor muscle.
It has been shown to significantly decrease the number or micturition episodes, urgency
episodes, and increased mean volume of urine voided per micturition. It also has a favorable
tolerability profile.